German-based Dynamic42, an organ-on-chip specialist, has successfully raised a mid-seven-figure financing round to support its growth and vision. The round was led by bm-t beteiligungsmanagement thüringen gmbh (bm-t), the previous lead investor, and a family office from the health sector. The funding will allow Dynamic42 to expand internationally, including a planned entry into the US pharmaceutical market. Dynamic42 offers miniaturized human organ models for drug testing that can be customized to meet individual client needs. The models can include essential components of the human immune system for investigating drug compatibility and the potential neural effects of drug candidates. The company’s technology has a high market potential as it offers better alternatives than current systems, reduces animal testing, and increases drug safety.
German company Dynamic42 secures Series A funding to expand globally with their organ-on-chip technology.
Date:
Updated: [falahcoin_post_modified_date]
More like thisRelated
Revolutionary Small Business Exchange Network Connects Sellers and Buyers
Revolutionary SBEN connects small business sellers and buyers, transforming the way businesses are bought and sold in the U.S.
District 1 Commissioner Race Results Delayed by Recounts & Ballot Reviews, US
District 1 Commissioner Race in Orange County faces delays with recounts and ballot reviews. Find out who will come out on top in this close election.
Fed Minutes Hint at Potential Rate Cut in September amid Economic Uncertainty, US
Federal Reserve minutes suggest potential rate cut in September amid economic uncertainty. Find out more about the upcoming policy decisions.
Baltimore Orioles Host First-Ever ‘Faith Night’ with Players Sharing Testimonies, US
Experience the powerful testimonies of Baltimore Orioles players on their first-ever 'Faith Night.' Hear how their faith impacts their lives on and off the field.
